VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Pathogen Page
Herpes simplex virus type 1 and 2

Table of Contents

  1. General Information
    1. NCBI Taxonomy ID
    2. Disease
    3. Introduction
    4. Microbial Pathogenesis
    5. Host Ranges and Animal Models
    6. Host Protective Immunity
  2. Vaccine Related Pathogen Genes
    1. gB
    2. gD
    3. gD
    4. gH
    5. ICP0
    6. ICP27
    7. ICP27 from Herpes simplex virus type 2
    8. TK
    9. UL27
    10. UL27 from Herpes simplex virus type 1
    11. UL29
    12. UL44 from HSV-1
    13. UL44 from HSV-2
    14. US4
    15. US5
    16. US6
    17. US7
    18. US8
  3. Vaccine Related Host Genes
    1. IgG
    2. Ighv1-9
  4. Vaccine Information
    1. GSK1437173A
    2. Herpes simplex virus 1 gD mutant vaccine
    3. Herpes simplex virus 1 gH mutant vaccine
    4. Herpes simplex virus 1 TK mutant vaccine
    5. Herpes simplex virus 1 UL29 mutant vaccine
    6. Herpes Simplex Virus 2 DNA Vaccine encoding gD
    7. Herpes Simplex Virus 2 DNA Vaccine encoding gD with CD40L
    8. Herpes Simplex Virus 2 DNA Vaccine Vaxfectin-gD2
    9. Herpes simplex virus 2 ICP0 mutant vaccine
    10. Herpes simplex virus DNA vaccine ∆gB-2 encoding gB
    11. Herpes simplex virus DNA vaccine encoding gD and gB from HSV-2 strain Curtis
    12. Herpes simplex virus DNA vaccine gB-DNA encoding gB
    13. Herpes simplex virus DNA vaccine gBDNA encoding gB
    14. Herpes simplex virus DNA vaccine gD-2 encoding gD
    15. Herpes simplex virus DNA vaccine ICP-27 DNA encoding ICP-27
    16. Herpes simplex virus DNA vaccine pCI-gB encoding gB
    17. Herpes simplex virus DNA vaccine pSIN-gB encoding gB
    18. Herpes Simplex Virus Type 1 DNA Vaccine encoding 5gP
    19. Herpes simplex virus type 1 DNA vaccine encoding GC
    20. Herpes simplex virus type 1 DNA vaccine encoding GD
    21. Herpes simplex virus type 1 DNA vaccine encoding GE
    22. Herpes Simplex Virus Type 1 DNA Vaccine pRSC-gD-IL-21
    23. Herpes simplex virus type 2 DNA vaccine encoding GB
    24. Herpes simplex virus type 2 DNA vaccine encoding ICP27
    25. Herpes simplex virus type 2 vaccine using phage displaying GG protein
    26. HSV 2 DNA vaccine pVAX–HSV–2gD–Hsp70
    27. HSV glycoproteins subunit vaccine
    28. pRP-RSV-HSV-1-gB
    29. rOka-gD2- HSV-2
  5. References
I. General Information
1. NCBI Taxonomy ID:
10298
2. Disease:
Herpes
3. Introduction
Herpes simplex virus 1 and 2 (HSV-1 and HSV-2), also known as Human herpes virus 1 and 2 (HHV-1 and -2), are two members of the herpes virus family, Herpesviridae, that infect humans. Both HSV-1 and -2 are ubiquitous and contagious. They can be spread when an infected person is producing and shedding the virus. Symptoms of herpes simplex virus infection include watery blisters in the skin or mucous membranes of the mouth, lips or genitals. Lesions heal with a scab characteristic of herpetic disease. However, as neurotropic and neuroinvasive viruses, HSV-1 and -2 persist in the body for the life of the carrier by becoming latent and hiding from the immune system in the cell bodies of nerves. After the initial or primary infection, some infected people experience sporadic episodes of viral reactivation or outbreaks. In an outbreak, the virus in a nerve cell becomes active and is transported via the nerve's axon to the skin, where virus replication and shedding occur and cause new sores.
There is no known cure for HSV infection, but treatments can reduce the likelihood of viral shedding and spread (Wiki: Herpes simplex virus).
4. Microbial Pathogenesis
In the case of a herpes virus, initial interactions occur when a viral envelope glycoprotein called glycoprotein C (gC) binds to a cell surface particle called heparan sulfate. A second glycoprotein, glycoprotein D (gD), binds specifically to at least one of three known entry receptors. These include herpesvirus entry mediator(HVEM), nectin-1 and 3-O sulfated heparan sulfate. The receptor provides a strong, fixed attachment to the host cell. These interactions bring the membrane surfaces into mutual proximity and allow for other glycoproteins embedded in the viral envelope to interact with other cell surface molecules. HSVs may persist in a quiescent but persistent form known as latent infection, notably in neural ganglia. HSV-1 tends to reside in the trigeminal ganglia, while HSV-2 tends to reside in the sacral ganglia, but note that these are tendencies only, not fixed behavior (Wiki: Herpes simplex virus).
5. Host Ranges and Animal Models
HSV-1 and HSV-2 infect humans and mice are used as a model of protection in vaccine studies (Nass et al., 1998).
6. Host Protective Immunity
HSV evades the immune system through interference with MHC class I presentation of antigen on the cell surface. This is achieved through blockade of the TAP transporter induced by the secretion of ICP-47 by HSV. TAP maintains the integrity of the MHC class I molecule before it is transported via the golgi apparatus for recognition by CD8+ CTLs on the cell surface. ICP-47 disrupts this integrity, preventing the capture of cytosolic proteins for CTL recognition and thus evades CTL destruction (Wiki: Herpes simplex virus).
Loading...
Loading Pathogen Genes...
Loading...
Loading Host Genes...
Loading...
Loading Vaccines...
Loading References...